Key facts
- It has raised $213.5M across 3 recorded rounds; the latest was Later Stage VC (Series E) ($57.0M) in Sep 2024.
- Notable investors include Khosla Ventures, MedTech Innovator, D1 Capital Partners, National Institutes of Health, StartX (US) — 23 tracked in total.
- Inflammatix has filed 2 Form Ds with the SEC since 2020, most recently Mar 2021 ($102.4M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Inflammatix
Funding rounds
3 roundsAbout Inflammatix
Developer of molecular diagnostics tests designed to interpret the immune system to diagnose acute infections and assess illness severity. The company's tests measure specific messenger RNA markers in blood samples to provide bacterial and viral infection likelihood and severity scores, enabling emergency departments to make timely clinical decisions and improve patient management with data-driven insights.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Sunnyvale, CA, United States
- Founded
- 2016
- Employees
- 93
- Website
- inflammatix.com/
- Ownership
- Privately Held (backing)
Inflammatix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inflammatix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inflammatix in its N-PORT filings yet. We sweep new filings monthly.